Literature DB >> 26937803

CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.

Ying Liu1, Jongphil Kim1, Fangyuan Qu1, Shichang Liu1, Hua Wang1, Yoganand Balagurunathan1, Zhaoxiang Ye1, Robert J Gillies1.   

Abstract

Purpose To retrospectively identify the relationship between epidermal growth factor receptor (EGFR) mutation status, predominant histologic subtype, and computed tomographic (CT) characteristics in surgically resected lung adenocarcinomas in a cohort of Asian patients. materials and Methods This study was approved by the institutional review board, with waiver of informed consent. Preoperative chest CT findings were retrospectively evaluated in 385 surgically resected lung adenocarcinomas. A total of 30 CT descriptors were assessed. EGFR mutations at exons 18-21 were determined by using the amplification refractory mutation system. Multiple logistic regression analyses were performed to identify independent factors of harboring EGFR mutation status. The final model was selected by using the backward elimination method, and two areas under the receiver operating characteristic curve (ROC) were compared with the nonparametric approach of DeLong, DeLong, and Clarke-Pearson. Results EGFR mutations were found in 168 (43.6%) of 385 patients. Mutations were found more frequently in (a) female patients (P < .001); (b)those who had never smoked (P < .001); (c)those with lepidic predominant adenocarcinomas (P = .001) or intermediate pathologic grade (P < .001); (e) smaller tumors (P < .001); (f)tumors with spiculation (P = .019), ground-glass opacity (GGO) or mixed GGO (P < .001), air bronchogram (P = .006), bubblelike lucency (P < .001), vascular convergence (P = .024), thickened adjacent bronchovascular bundles (P = .027), or pleural retraction (P < .001); and (g) tumors without pleural attachment (P = .004), a well-defined margin (P = .010), marked heterogeneous enhancement (P = .001), severe peripheral emphysema (P = .002), severe peripheral fibrosis (P = .013), or lymphadenopathy (P = .028). The most important and significantly independent prognostic factors of harboring EGFR-activating mutation for the model with both clinical variables and CT features were those who had never smoked and those with smaller tumors, bubblelike lucency, homogeneous enhancement, or pleural retraction when adjusting for histologic subtype, pathologic grade, or thickened adjacent bronchovascular bundles. ROC curve analysis showed that use of clinical variables combined with CT features (area under the ROC curve = 0.778) was superior to use of clinical variables alone (area under the ROC curve = 0.690). Conclusion CT imaging features of lung adenocarcinomas in combination with clinical variables can be used to prognosticate EGFR mutation status better than use of clinical variables alone. (©) RSNA, 2016 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26937803      PMCID: PMC4934516          DOI: 10.1148/radiol.2016151455

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  29 in total

1.  Epidermal growth factor receptor mutation status in stage I lung adenocarcinoma with different image patterns.

Authors:  Kuo-Hsuan Hsu; Kun-Chieh Chen; Tsung-Ying Yang; Yi-Chen Yeh; Teh-Ying Chou; Hsuan-Yu Chen; Chi-Ren Tsai; Chih-Yi Chen; Chung-Ping Hsu; Jiun-Yi Hsia; Cheng-Yen Chuang; Ying-Huang Tsai; Kuan-Yu Chen; Ming-Shyan Huang; Wu-Chou Su; Yuh-Min Chen; Chao A Hsiung; Gee-Chen Chang; Chien-Jen Chen; Pan-Chyr Yang
Journal:  J Thorac Oncol       Date:  2011-06       Impact factor: 15.609

2.  Solitary pulmonary nodule: high-resolution CT and radiologic-pathologic correlation.

Authors:  C V Zwirewich; S Vedal; R R Miller; N L Müller
Journal:  Radiology       Date:  1991-05       Impact factor: 11.105

3.  ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens.

Authors:  Jinguo Liu; Ruiying Zhao; Jie Zhang; Jian Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-26       Impact factor: 4.553

4.  Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.

Authors:  Yang Zhang; Yihua Sun; Yunjian Pan; Chenguang Li; Lei Shen; Yuan Li; Xiaoyang Luo; Ting Ye; Rui Wang; Haichuan Hu; Hang Li; Lei Wang; William Pao; Haiquan Chen
Journal:  Clin Cancer Res       Date:  2012-02-08       Impact factor: 12.531

5.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim Geisinger; Yasushi Yatabe; Charles A Powell; David Beer; Greg Riely; Kavita Garg; John H M Austin; Valerie W Rusch; Fred R Hirsch; James Jett; Pan-Chyr Yang; Michael Gould
Journal:  Proc Am Thorac Soc       Date:  2011-09

6.  High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.

Authors:  Ping-Li Sun; Hyesil Seol; Hyun Ju Lee; Seol Bong Yoo; Hyojin Kim; Xianhua Xu; Sanghoon Jheon; Choon-Taek Lee; Jong-Suk Lee; Jin-Haeng Chung
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

7.  Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

Authors:  Qing Zhou; Xu-Chao Zhang; Zhi-Hong Chen; Xiao-Lu Yin; Jin-Ji Yang; Chong-Rui Xu; Hong-Hong Yan; Hua-Jun Chen; Jian Su; Wen-Zhao Zhong; Xue-Ning Yang; She-Juan An; Bin-Chao Wang; Yi-Sheng Huang; Zhen Wang; Yi-Long Wu
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

8.  Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.

Authors:  Akihiko Yoshizawa; Shinji Sumiyoshi; Makoto Sonobe; Masashi Kobayashi; Masakazu Fujimoto; Fumi Kawakami; Tatsuaki Tsuruyama; William D Travis; Hiroshi Date; Hironori Haga
Journal:  J Thorac Oncol       Date:  2013-01       Impact factor: 15.609

9.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

10.  Advanced lung adenocarcinoma harboring a mutation of the epidermal growth factor receptor: CT findings after tyrosine kinase inhibitor therapy.

Authors:  Chang-Min Choi; Mi Young Kim; Jae Cheol Lee; Hwa Jung Kim
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

View more
  80 in total

1.  Computed Tomography-Based Radiomics Signature: A Potential Indicator of Epidermal Growth Factor Receptor Mutation in Pulmonary Adenocarcinoma Appearing as a Subsolid Nodule.

Authors:  Xinguan Yang; Xiao Dong; Jiao Wang; Weiwei Li; Zhuoran Gu; Dashan Gao; Nanshan Zhong; Yubao Guan
Journal:  Oncologist       Date:  2019-04-01

2.  Patient factors to consider before lung cancer screening.

Authors:  Chin A Yi; Tae Jung Kim; Kyung Soo Lee
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

3.  Representation of Deep Features using Radiologist defined Semantic Features.

Authors:  Rahul Paul; Ying Liu; Qian Li; Lawrence Hall; Dmitry Goldgof; Yoganand Balagurunathan; Matthew Schabath; Robert Gillies
Journal:  Proc Int Jt Conf Neural Netw       Date:  2018-09-15

4.  CT diagnosis of pleural and stromal invasion in malignant subpleural pure ground-glass nodules: an exploratory study.

Authors:  Qing Zhao; Jian-Wei Wang; Lin Yang; Li-Yan Xue; Wen-Wen Lu
Journal:  Eur Radiol       Date:  2018-06-25       Impact factor: 5.315

5.  Prognostic value and molecular correlates of a CT image-based quantitative pleural contact index in early stage NSCLC.

Authors:  Juheon Lee; Yi Cui; Xiaoli Sun; Bailiang Li; Jia Wu; Dengwang Li; Michael F Gensheimer; Billy W Loo; Maximilian Diehn; Ruijiang Li
Journal:  Eur Radiol       Date:  2017-08-07       Impact factor: 5.315

Review 6.  Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology.

Authors:  Jian-Wei Gao; Stefania Rizzo; Li-Hong Ma; Xiang-Yu Qiu; Arne Warth; Nobuhiko Seki; Mizue Hasegawa; Jia-Wei Zou; Qian Li; Marco Femia; Tang-Feng Lv; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2017-02

7.  Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations.

Authors:  Robert J Gillies; Zhaoxiang Ye; Hua Wang; Matthew B Schabath; Ying Liu; Ying Han; Qi Li
Journal:  Eur J Radiol       Date:  2016-08-30       Impact factor: 3.528

8.  Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer.

Authors:  Emmanuel Rios Velazquez; Chintan Parmar; Ying Liu; Thibaud P Coroller; Gisele Cruz; Olya Stringfield; Zhaoxiang Ye; Mike Makrigiorgos; Fiona Fennessy; Raymond H Mak; Robert Gillies; John Quackenbush; Hugo J W L Aerts
Journal:  Cancer Res       Date:  2017-05-31       Impact factor: 12.701

Review 9.  Targeting acidity in cancer and diabetes.

Authors:  Robert J Gillies; Christian Pilot; Yoshinori Marunaka; Stefano Fais
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-01-30       Impact factor: 10.680

10.  Epidermal growth factor receptor mutations in lung adenocarcinoma: associations between dual-energy spectral CT measurements and histologic results.

Authors:  Guojin Zhang; Junlin Zhou; Yuntai Cao; Jing Zhang; Zhiyong Zhao; Wenjuan Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-26       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.